155 related articles for article (PubMed ID: 31336733)
1. A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.
Stackhouse CT; Rowland JR; Shevin RS; Singh R; Gillespie GY; Willey CD
Cells; 2019 Jul; 8(7):. PubMed ID: 31336733
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions.
Gilbert AN; Anderson JC; Duarte CW; Shevin RS; Langford CP; Singh R; Gillespie GY; Willey CD
Sci Rep; 2018 May; 8(1):8412. PubMed ID: 29849102
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
4. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
[TBL] [Abstract][Full Text] [Related]
5. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
7. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
[TBL] [Abstract][Full Text] [Related]
8. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
9. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
10. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
Radaelli E; Ceruti R; Patton V; Russo M; Degrassi A; Croci V; Caprera F; Stortini G; Scanziani E; Pesenti E; Alzani R
Histol Histopathol; 2009 Jul; 24(7):879-91. PubMed ID: 19475534
[TBL] [Abstract][Full Text] [Related]
11. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
12. Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies.
Kerstetter-Fogle AE; Harris PLR; Brady-Kalnay SM; Sloan AE
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698368
[TBL] [Abstract][Full Text] [Related]
13. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.
Tseng JH; Chen CY; Chen PC; Hsiao SH; Fan CC; Liang YC; Chen CP
Oncotarget; 2017 Feb; 8(9):14666-14679. PubMed ID: 28108734
[TBL] [Abstract][Full Text] [Related]
16. Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.
William D; Mullins CS; Schneider B; Orthmann A; Lamp N; Krohn M; Hoffmann A; Classen CF; Linnebacher M
J Transl Med; 2017 Feb; 15(1):27. PubMed ID: 28183348
[TBL] [Abstract][Full Text] [Related]
17. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
18. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
19. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
20. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
